Erstellt von gina_evans0312
vor fast 11 Jahre
|
||
Age of host
EBV Carriers at Risk of Cancer
Virus Integration
Genome Size & Type
Genome Stability
Latency
Avoiding Immune Surveillance- Avoid Cytotoxic T-Cell
Avoiding Immune Surveillance- Latency
Avoiding Immune Surveillance- Response Modification
Source of Infection
Site of Infection
CD21
GP350
Viral Replication Cycle
Characteristic Of Lytic Replication
Exit From Cell
Viral DNA Polymerase
Products of Latency Stage
Length of Infection Before Latency is Activated
Host DNA Polymerase